Press Releases Featured Image

Press Releases

All Releases

Blackstone Life Sciences Launches Uniquity Bio to Develop Novel Medicines in Immunology & Inflammation

Blackstone announced the launch of the Blackstone Life Sciences (“Blackstone”) portfolio company Uniquity Bio, a clinical-stage drug development company focused on immunology and inflammation. Uniquity Bio is emerging from stealth with an FDA acceptance of its Phase 2 investigational new drug (“IND”) application for solrikitug, a monoclonal antibody targeting TSLP, and up to $300 million in capital from Blackstone to advance the asset in multiple indications.

Blackstone Announces Plans to Commence a Tender Offer for I’rom Group, One of Japan’s Leading Site Management Organizations, a Mission-Critical Function of Clinical Trials

Blackstone (NYSE:BX) announced today that private equity funds and vehicles managed by Blackstone (“Blackstone”) have entered into a definitive agreement with Toyotaka Mori (“Mr. Mori”), Founder, President & Chief Executive Officer of I’rom Group Co., Ltd. (“I’rom”; TSE stock code 2372), Japan’s leading Site Management Organization (SMO), to jointly take I’rom private. I’rom provides clinical trial management services to pharmaceutical, biotechnology, and medical institutions, and plays a critical role in the success of clinical trials, ensuring that new technologies and medicines are brought to the market efficiently and quickly.

Stay up to date